Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

EO 2401

Next Previous
Drug Profile

EO 2401

Alternative Names: EO 2401

Latest Information Update: 20 Nov 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Enterome
  • Class Antineoplastics; Bacterial vaccines; Cancer vaccines; Immunotherapies; Peptide vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase I/II Adrenocortical carcinoma; Glioblastoma; Phaeochromocytoma
  • No development reported Solid tumours

Most Recent Events

  • 12 Nov 2024 Enterome terminated a phase I/II trial in Adrenocortical carcinoma and Phaechromocytoma (Combination therapy, First-line therapy, Second-line therapy or greater, Inoperable/Unresectable, Late-stage disease, Metastatic disease) in Sweden, Denmark, USA (SC)due to strategic decision (NCT04187404)
  • 24 May 2024 EO 2401 is available for licensing as of 24 May 2024. http://www.enterome.com
  • 04 Mar 2024 Enterome completes the phase I/II ROSALIE trial in Glioblastoma (Combination therapy, Recurrent, Second-line therapy or greater) in USA, France, Germany, Spain (NCT04116658)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top